We don't yet know. A range of autoimmune diseases that affect various organ systems and cause muscle wasting may be good candidates (mouse and preliminary human studies suggest) for GLP-1 receptor agonist treatment because of their ability to reduce the expression and release of inflammatory cytokines
Therefore, they may choose to maintain a lower dose if it causes fewer gastrointestinal symptoms
While not generalizable to polygenic obesity, these targeted treatments mark a key advance in personalized obesity care (Figs
Retatrutide, a new weight loss drug, is generating buzz for its extensive list of benefits beyond just weight loss
LJ, RMA, SG, BL and YT are guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis
Extensive frontal focused ultrasound mediated bloodbrain barrier opening for the treatment of Alzheimers disease: A proof-of-concept study